Literature DB >> 28839979

Nodal downstaging in esophageal and esophagogastric junction cancer: more important than ever.

Andrea Zanoni1,2.   

Abstract

Entities:  

Year:  2017        PMID: 28839979      PMCID: PMC5542932          DOI: 10.21037/jtd.2017.06.126

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  15 in total

1.  7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction.

Authors:  Thomas W Rice; Eugene H Blackstone; Valerie W Rusch
Journal:  Ann Surg Oncol       Date:  2010-07       Impact factor: 5.344

2.  Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.

Authors:  A Zanoni; G Verlato; S Giacopuzzi; J Weindelmayer; F Casella; F Pasini; E Zhao; G de Manzoni
Journal:  Ann Surg Oncol       Date:  2012-12-29       Impact factor: 5.344

3.  Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

Authors:  Katrin M Sjoquist; Bryan H Burmeister; B Mark Smithers; John R Zalcberg; R John Simes; Andrew Barbour; Val Gebski
Journal:  Lancet Oncol       Date:  2011-06-16       Impact factor: 41.316

4.  Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.

Authors:  Paul M Schneider; Stephan E Baldus; Ralf Metzger; Martin Kocher; Rudolf Bongartz; Elfriede Bollschweiler; Hartmut Schaefer; Juergen Thiele; Hans P Dienes; Rolf P Mueller; Arnulf H Hoelscher
Journal:  Ann Surg       Date:  2005-11       Impact factor: 12.969

5.  Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT).

Authors:  Stephen G Swisher; Wayne Hofstetter; Tsung T Wu; Arlene M Correa; Jaffer A Ajani; Ritsuko R Komaki; Lucian Chirieac; Kelly K Hunt; Zhongxing Liao; Alexandria Phan; David C Rice; Ara A Vaporciyan; Garrett L Walsh; Jack A Roth
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

6.  Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma.

Authors:  Arnulf H Hölscher; Uta Drebber; Henner Schmidt; Efriede Bollschweiler
Journal:  Ann Surg       Date:  2014-11       Impact factor: 12.969

7.  Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

Authors:  Val Gebski; Bryan Burmeister; B Mark Smithers; Kerwyn Foo; John Zalcberg; John Simes
Journal:  Lancet Oncol       Date:  2007-03       Impact factor: 41.316

8.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations.

Authors:  A M Mandard; F Dalibard; J C Mandard; J Marnay; M Henry-Amar; J F Petiot; A Roussel; J H Jacob; P Segol; G Samama
Journal:  Cancer       Date:  1994-06-01       Impact factor: 6.860

9.  Survival in lymph node negative adenocarcinoma of the esophagus after R0 resection with and without neoadjuvant therapy: evidence for downstaging of N status.

Authors:  Jessica M Leers; Shahin Ayazi; Jeffrey A Hagen; Sergei Terterov; Nancy Klipfel; Arzu Oezcelik; Emmanuele Abate; John C Lipham; Steven R DeMeester; Farzaneh Banki; Tom R DeMeester
Journal:  J Am Coll Surg       Date:  2009-04       Impact factor: 6.113

10.  Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.

Authors:  Fergus Noble; Luke Nolan; Adrian C Bateman; James P Byrne; Jamie J Kelly; Ian S Bailey; Donna M Sharland; Charlotte N Rees; Timothy J Iveson; Tim J Underwood; Andrew R Bateman
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

View more
  1 in total

1.  Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction.

Authors:  S K Kamarajah; M Navidi; S Wahed; A Immanuel; N Hayes; S M Griffin; A W Phillips
Journal:  Ann Surg Oncol       Date:  2020-03-21       Impact factor: 5.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.